Skip to main content
Prime Medicine, Inc. logo

Prime Medicine, Inc. — Investor Relations & Filings

Ticker · PRME ISIN · US74168J1016 US Manufacturing
Filings indexed 259 across all filing types
Latest filing 2025-03-04 Director's Dealing
Country US United States of America
Listing US PRME

About Prime Medicine, Inc.

https://primemedicine.com/

Prime Medicine, Inc. is a biotechnology company focused on developing a new class of one-time, curative genetic therapies. The company's approach is centered on its proprietary Prime Editing platform, a next-generation gene editing technology. Prime Editing is designed to function like a precise 'search and replace' mechanism for the genome, capable of correcting a wide range of disease-causing genetic mutations. It can perform insertions, deletions, and all types of point mutations without inducing double-strand DNA breaks, a key differentiator from some earlier gene editing techniques. The company's mission is to address the root genetic cause of debilitating diseases, aiming to provide patients with potentially lifelong therapeutic benefits.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-03-04 English
FORM 4
Director's Dealing
2025-03-04 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Prime Medicine, Inc. It registers additional shares of common stock under the company's 2022 Stock Option and Incentive Plan. The document includes legal and procedural information related to the registration of securities, exhibits, and signatures of company officers. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits the category of Regulatory Filings (RNS). The document length (8040 characters) and content confirm it is not a brief announcement or a full financial report but a formal registration statement filing.
2025-02-28 English
10-K
Annual Report FY 2024
2025-02-28 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 28, 2025, by Prime Medicine, Inc. It announces the issuance of a press release containing financial results and business highlights for the year ended December 31, 2024. The document explicitly states that the press release is furnished as an exhibit and is not filed for purposes of Section 18 of the Exchange Act, indicating this is an announcement of financial results rather than the full report itself. The length of the document is 3728 characters, which is relatively short and consistent with a report publication or announcement rather than a full earnings release or annual report. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to earnings releases or financial results announcements. Given the short length and nature of the document, it fits best as an Earnings Release (ER) announcement rather than a full Annual Report (10-K) or Interim Report (IR).
2025-02-28 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.